Anup Sharma, PhD
Research Scientist of SurgeryCards
Appointments
Surgery
Primary
Contact Info
About
Titles
Research Scientist of Surgery
Appointments
Surgery
Research ScientistPrimary
Other Departments & Organizations
- Ahuja Lab
- Genomics, Genetics, and Epigenetics
- Surgery
- Yale Cancer Center
Education & Training
- Post Doctoral Fellow
- The Johns Hopkins University
- PhD
- University of Melbourne
Research
Overview
My research focuses on a better understanding of epigenetic mechanisms pertaining to Pancreatic Cancer initiation and progression. I am also developing novel liquid biopsy-based technologies to analyze cell-free DNA in early cancer detection and to monitor therapeutic responses to chemotherapy.
I am also interested in the disparities in cancer outcomes with a special focus on the implications of racial diversity in the molecular landscape of pancreatic cancer.
Research at a Glance
Yale Co-Authors
Frequent collaborators of Anup Sharma's published research.
Publications Timeline
A big-picture view of Anup Sharma's research output by year.
Nita Ahuja, MD, MBA, FACS
John Kunstman, MD, MHS, FACS
Lee Ying, MD, PhD, MS, MPhil
Alyssa Ann Grimshaw, MBA, MLIS, MPH
Ankit Chhoda, MBBS, MD
Bony De Kumar, PhD
7Publications
49Citations
Publications
2024
Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology
Tan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B, He L, Sharma A, Ahuja N. Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology. Current Issues In Molecular Biology 2024, 46: 6533-6565. PMID: 39057032, PMCID: PMC11276574, DOI: 10.3390/cimb46070390.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCell-free DNA liquid biopsyCell-free DNALiquid biopsy technologiesLiquid biopsyBiopsy technologyEarly cancer detectionClinical applicationCfDNA-based liquid biopsyMonitoring residual diseaseEarly detection testsCancer detectionPotential of epigeneticsPersonalized cancer treatmentImprove cancer outcomesTissue of originFragmentation pattern analysisResidual diseaseDNA methylationMulti-cancer early detection testTreatment responseBiopsyCancer outcomesCancer preventionEpigeneticsPrecision oncologyProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchConceptsFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factors
2023
Early Detection of Cancers in the Era of Precision Oncology
Tan W, Sharma A, Das P, Ahuja N. Early Detection of Cancers in the Era of Precision Oncology. Current Opinion In Oncology 2023, 35: 115-124. PMID: 36721896, DOI: 10.1097/cco.0000000000000931.Peer-Reviewed Original ResearchCitationsAltmetricUtility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms
Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPapillary mucinous neoplasmMalignant risk stratificationCACNA1G geneRisk stratificationMucinous neoplasmsBiomarker panelBackgroundIntraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmEarly detectionPrevious case-control studyHigh-grade dysplasiaCase-control studyPancreatic cancer precursorsReceiver Operating Characteristic (ROC) curve analysisSignificant diagnostic challengeCross-sectional imagingCharacteristic curve analysisOperating Characteristic curve analysisG geneHigh diagnostic specificityPrior validation studiesSignificant procedural riskIPMN tissuesSurgical resectionAdvanced neoplasia
2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsResectable pancreatic ductal adenocarcinomaCC-486OBS patientsMetastatic settingAdjuvant therapyTreatment-related grade 3Randomized phase II studyMedian age 66Next-line therapyResultsForty-nine patientsMedian treatment durationPhase II studyEvidence of diseaseHigh-risk featuresPhase II trialProgression-free survivalStandard adjuvant therapyPancreatic ductal adenocarcinomaCancer recursEvaluable patientsMedian OSMedian PFSOral azacitidineR1 resectionSubsequent chemotherapy
2021
Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study
Yaghoobi V, Moutafi M, Aung TN, Pelekanou V, Yaghoubi S, Blenman K, Ibrahim E, Vathiotis IA, Shafi S, Sharma A, O’Meara T, Fernandez AI, Pusztai L, Rimm DL. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study. Breast Cancer Research 2021, 23: 113. PMID: 34906209, PMCID: PMC8670126, DOI: 10.1186/s13058-021-01493-w.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNegative breast cancerT cellsTumor microenvironmentAA patientsImmune cellsAA tumorsBreast cancerPurposeTriple-negative breast cancerAfrican AmericansTriple-negative breast cancerCase-control studySignificant differencesActivated T cellsImmunologic biomarkersPD-L1Lymphocytic infiltrationLymphoid infiltrationImmune microenvironmentControl cohortTNBC tumorsMyeloid markersQuantitative immunofluorescenceMean expression levelPatientsTNBCLate-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis
Chhoda A, Vodusek Z, Wattamwar K, Mukherjee E, Gunderson C, Grimshaw A, Sharma A, Ahuja N, Kastrinos F, Farrell JJ. Late-Stage Pancreatic Cancer Detected During High-Risk Individual Surveillance: A Systematic Review and Meta-Analysis. Gastroenterology 2021, 162: 786-798. PMID: 34813861, DOI: 10.1053/j.gastro.2021.11.021.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLate-stage PDACPancreatic ductal adenocarcinomaHigh-risk individualsHigh-grade precursorsCumulative incidenceAdvanced neoplasiaLate-stage pancreatic cancerTiming of presentationRandom-effects modelWeb of ScienceClinicoradiologic factorsClinicoradiologic featuresSurveillance imagingCochrane LibraryPancreatic cancerDuctal adenocarcinomaPancreatic morphologySurveillance studyFunnel plotLesion sitePDAC stagesSurveillance adherenceSystematic reviewMeta-AnalysisSignificant association
Academic Achievements & Community Involvement
honor Young Investigator Award
International AwardAsian-Pacific Society on Thromb & HemostDetails04/02/2012Australiahonor Young Investigator Award
International AwardInternational Society on Thromb & HaemostDetails04/01/2011Japan
News
News
- September 25, 2024
Pancreatic Cysts: A Q&A with James Farrell, MD
- June 30, 2023
Pancreatic Cancer Risk Lower if Cysts Remain Stable for Five Years
- June 16, 2022
Discoveries & Impact (June 2022)
Get In Touch
Contacts
Email